Dr Lal Pathlabs Ltd (LALPATHLAB) — shareholding pattern, promoter holding, financials and share price
About Dr Lal Pathlabs Ltd (LALPATHLAB)
Dr Lal Pathlabs Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as LALPATHLAB and on the BSE under scrip code 539524. Its ISIN is INE600L01024.
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
Dr. Lal PathLabs is a leading diagnostic healthcare service provider in India, offering over 5000 tests through an extensive national network of labs and service centers.
Despite industry challenges, the company achieved a 10.6% YoY increase in revenue for Q3 FY26, underscoring its ability to sustain growth through strategic moves like network expansion and introduction of new tests.
Listed peers in Healthcare Service Provider: Vijaya Diagnostic Centre Ltd, Metropolis Healthcare Ltd, Thyrocare Technologies Ltd, Nephrocare Health Services Ltd, Krsnaa Diagnostics Ltd, Suraksha Diagnostic Ltd.
Valuation & Returns
10 Jul 2026At ₹1,685.1 a share on 10 Jul 2026, Dr Lal Pathlabs Ltd (LALPATHLAB) was valued at a price-to-earnings ratio of 55.41x against an industry P/E of 61.73x and a price-to-book of 11.26x on a book value of ₹149.62 per share as of Mar 2026. Solomo computes return on equity of 20.33% and return on capital employed of 25.56% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 55.41x
- Industry P/E
- 61.73x
- P/B
- 11.26x
- EPS (TTM)
- ₹30.41
- Book value / share
- ₹149.62
- ROE
- 20.33%
- ROCE
- 25.56%
- ROA
- 16.2%
- Debt / equity
- 0.08x
- Dividend yield
- 1.22%
- EBITDA margin
- 30.9%
- 52-week range
- ₹1,272 – ₹1,803.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Dr Lal Pathlabs Ltd (LALPATHLAB) reported revenue of ₹2,763 crore, net profit of ₹510 crore and earnings per share of ₹30.13. That compares with revenue of ₹2,461 crore and net profit of ₹492 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹703 crore and net profit ₹132 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 |
| Net profit (₹ cr) | 350 | 241 | 362 | 492 | 510 |
| EPS (₹) | 20.69 | 14.33 | 21.42 | 29.14 | 30.13 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 12.99% | 12.18% | 14.39% | 12.25% |
| Profit growth | 14.31% | 12.65% | 20.24% | 3.56% |
| Stock price CAGR | 13% | 0% | 14% | 16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 53.19% of Dr Lal Pathlabs Ltd (LALPATHLAB) (down 0.02 pp QoQ), foreign institutional investors (FII) hold 17.36% and domestic institutional investors (DII) hold 21.59%. Market capitalisation was ₹28,249 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2015.
Largest disclosed public shareholders in Jun 2026: HDFC MUTUAL FUND - HDFC RETIREMENT SAVINGS FUND - EQUITY PLAN 3.91%, UTI-MID CAP FUND 2.64%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND 2.63%, Smallcap World Fund, Inc 1.98%, ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE SMALL CAP FUND 1.78%, Life Insurance Corporation Of India 1.47%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 53.19% | - | 17.36% | 21.59% | 46.43% |
| Mar 2026 | 53.21% | - | 17.18% | 21.38% | 46.44% |
| Dec 2025 | 53.21% | - | 20.29% | 19.21% | 46.44% |
| Sep 2025 | 53.21% | - | 21.86% | 18.49% | 46.42% |
| Jun 2025 | 53.79% | - | 21.68% | 17.91% | 45.82% |
| Mar 2025 | 53.91% | - | 23.91% | 16.08% | 45.83% |
| Dec 2024 | 53.91% | - | 26.82% | 13.17% | 45.81% |
| Sep 2024 | 53.92% | - | 26.82% | 12.89% | 45.75% |